Skip to content

Janux Therapeutics JANX Income Statement

FY'25FY'24FY'23FY'22
$10M-5.6%$10.59M+31.0%$8.08M-6.1%$8.61M+137%
$125.9M+84.1%$68.39M+24.5%$54.92M+2.8%$53.44M+104%
$41.77M+1.8%$41.05M+57.0%$26.14M+17.4%$22.26M+116%
$167.67M+53.2%$109.44M+35.0%$81.06M+7.1%$75.7M+107%
-$157.67M-59.5%-$98.85M-35.4%-$72.98M-8.8%-$67.09M-104%
-1,576.7%-643pp-933.6%-30.7pp-902.9%-124pp-779%+126pp
$44.04M+47.5%$29.85M+103%$14.69M+264%$4.03M+1,469%
$44.04M+47.5%$29.85M+103%$14.69M+264%$4.03M+1,469%
-$113.63M-64.7%-$68.99M-18.4%-$58.29M+7.6%-$63.06M-93.0%
-1,136.3%-485pp-651.6%+69.6pp-721.2%+11.0pp-732.2%+166pp
-$1.83-44.1%-$1.27+4.5%-$1.33+12.5%-$1.52+52.9%
-$1.83-44.1%-$1.27+4.5%-$1.33+12.5%-$1.52-9.4%
247.7M+16.9%211.9M+22.2%173.3M+4.6%165.8M+119%
247.7M+16.9%211.9M+22.2%173.3M+4.6%165.8M
$44.04M+47.5%$29.85M+103%$14.69M+264%$4.03M+1,469%
-$157.67M-59.5%-$98.85M-35.4%-$72.98M-8.8%-$67.09M-104%
-$155.64M-60.8%-$96.79M-36.3%-$71.02M-7.2%-$66.25M-102%
-$155.64M-60.8%-$96.79M-36.3%-$71.02M-7.2%-$66.25M-102%
-1,556.4%-642pp-914.1%-35.4pp-878.7%-109pp-769.3%+133pp
-$157.67M-59.5%-$98.85M-35.4%-$72.98M-8.8%-$67.09M-104%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Janux Therapeutics's revenue?
Janux Therapeutics (JANX) generated $13.7M in revenue over the trailing twelve months, up 47.1% year over year.
Is Janux Therapeutics profitable?
Janux Therapeutics is not currently profitable: it reported a net loss of $114.5M over the trailing twelve months, a -833.6% net margin.
What is Janux Therapeutics's earnings per share?
Janux Therapeutics's diluted EPS over the trailing twelve months is $-1.84.
Where does Janux Therapeutics's income statement data come from?
Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.